This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (30)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Delmar R. Caldwell, MD; Charles R. Salisbury, MD; James P. Guzek, MD

Arch Ophthalmol. 1984;102(4):539-540.

Abstract
• Betaxolol, a new β₁-adrenergic blocker, was applied to 20 eyes of ten patients with ocular hypertension. Topical 0.25% betaxolol was found to significantly lower intraocular pressure compared with placebo. There were no subjective or objective ocular or systemic side effects detected. There were no changes in pulse rate, BP, or corneal sensitivity. Betaxolol may be useful in patients with asthma, chronic bronchitis, and certain cardiovascular diseases where timolol maleate therapy may be contraindicated.

Author Affiliations
From the Department of Ophthalmology, Tulane Medical Center, New Orleans.

Footnotes
Accepted for publication April 26, 1983.

Reprint requests to Department of Ophthalmology, Tulane Medical Center, 1430 Tulane Ave, New Orleans, LA 70112 (Dr Caldwell).

This study was supported in part by Alcon Laboratories, Fort Worth, Tex.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Randomized Clinical Trials on Medical Treatment of Glaucoma: Are They Appropriate to Guide Clinical Practice?
Rossetti et al.
Arch Ophthalmol 1993;111:96-103.
ABSTRACT  

Apraclonidine: A One-Week Dose-Response Study
Jampel et al.
Arch Ophthalmol 1988;106:1069-1073.
ABSTRACT  

Additive Effect of Betaxolol and Epinephrine in Primary Open Angle Glaucoma
Allen and Epstein
Arch Ophthalmol 1986;104:1178-1184.
ABSTRACT  

Betaxolol vs Timolol: A Six-Month Double-blind Comparison
Stewart et al.
Arch Ophthalmol 1986;104:46-48.
ABSTRACT